Spark Therapeutics (ONCE) is Initiated by Chardan Capital Markets to Neutral, Price Target at $45

Spark Therapeutics (ONCE) is Initiated by Chardan Capital Markets to Neutral according to the research report released to the investors. The brokerage firm has set the Price Target of the shares at $45. The shares recommendation by the Brokerage Firm was released on Dec-24-2015.

Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) ended Thursday session in red amid volatile trading. The shares closed down 0.09 points or 0.2% at $45.52 with 506,235 shares getting traded. Post opening the session at $45.98, the shares hit an intraday low of $44.78 and an intraday high of $46.44 and the price vacillated in this range throughout the day. The company has a market cap of $1,125 million and the number of outstanding shares has been calculated to be 24,712,721 shares. The 52-week high of Spark Therapeutics, Inc. (NASDAQ:ONCE) is $79.5 and the 52-week low is $36.96.

Analysts at Zacks have given a short term rating of hold on Spark Therapeutics, Inc. (NASDAQ:ONCE) with a rank of 3. The shares has received an average rating of 1.5 from 4 brokerage firms. 3 analysts have rated the company as a strong buy. The shares has been rated as hold from 1 Wall Street Analysts.

Spark Therapeutics, Inc. (NASDAQ:ONCE) shares are expected to touch $82.33 in the short term. This short term price target has been shared by 3 analysts. However, the standard deviation of short term price estimate has been valued at 7.51. The target price could hit $90 on the higher end and $75 on the lower end.

Spark Therapeutics, Inc. has lost 10.73% in the last five trading days and dropped 12.29% in the last 4 weeks. Spark Therapeutics, Inc. has dropped 2.88% during the last 3-month period . Year-to-Date the stock performance stands at -1.04%.